<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497536</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001912-21</org_study_id>
    <nct_id>NCT00497536</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of IAsp Following CSII in Patients With T1DM</brief_title>
  <official_title>Pharmacokinetics of Insulin Aspart (IAsp) Following Continuous Subcutaneous Insulin Infusion (CSII) in Patients With Type 1 Diabetes Mellitus (T1DM)- Basal Rate Resolution.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare SSPIAsp during CSII giving one bolus per
      hour compared with multiple boluses per hour.

      The secondary objective is to compare SSPIAsp during continuous subcutaneous insulin infusion
      (CSII) versus continuous intravenous insulin infusion (CIII).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapid acting insulin, like insulin aspart, can be administered as CSII. The insulin can be
      administered as a basal rate with additional insulin administration from the pump related to
      mealtimes.

      Insulin is physiologically secreted in a pulsate manner from the pancreatic β-cells with a
      period of 5-10 minutes, and this is responsible for plasma insulin oscillations with similar
      frequency. The oscillatory pattern is believed to optimize control mechanisms of insulin to
      enhance its action on metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CV SSPIasp</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>≈ bolus protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>≈ CSII protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>≈ CIII protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart (IAsp)</intervention_name>
    <description>IAsp 100 U.
≈ bolus protocol: From 6 pm until 6 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm
1 dose/h + 50 % s.c. (≈ bolus).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart (IAsp).</intervention_name>
    <description>IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart (IAsp)</intervention_name>
    <description>IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (T1DM)

          -  Insulin pump users' ≥ 48 hours, 24 h dose &lt; 80 U

          -  Insulin dose ≥ 0,4 IE/kg/24hours

          -  18 years &lt; age &lt; 50 years

          -  Time since diagnosis of T1DM ≥ 5 years

          -  HbA1c ≤ 8,5 %

          -  Safe anticonceptive for fertile women

          -  Being able to understand and read Danish

        Exclusion Criteria:

          -  Dysregulation of endocrine disorders other than type 1 diabetes mellitus

          -  Severe dysregulation of diabetes mellitus

          -  Other severe adverse disease

          -  Pregnancy, planning pregnancy, or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsten Lauritzen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torben Laursen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicinsk Endokrinologisk Afdeling M</name>
      <address>
        <city>Aarhus C</city>
        <state>Region Midtjylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2007</study_first_submitted>
  <study_first_submitted_qc>July 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Charlotte Amalie Ihlo</name_title>
    <organization>University of Aarhus</organization>
  </responsible_party>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Continuous Subcutaneous Insulin Infusion (CSII)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

